Acute Myeloid Leukemia – Unmet Need – Unmet Need – First-Line Intensive-Induction-Eligible Acute Myeloid Leukemia (US/EU)
Acute myeloid leukemia (AML) is the most common acute leukemia in adults, originating from mutant myeloid precursor cells. Presently, the AML drug market is dominated by chemotherapy backbones, but recent drug approvals suggest a shift toward targeted agents. Approximately 70% of patients treated with cytotoxic chemotherapy achieve complete remission. Nevertheless, the five-year relative survival rate is only 30.5%. In this report, we focus on the unmet need in the first-line treatment of intensive-induction-eligible AML. These patients currently receive cytotoxic chemotherapy, with or without biomarker-driven targeted therapies (such as Mylotarg and Rydapt) or the topoisomerase II inhibitor Vyxeos.
QUESTIONS ANSWERED
- What treatment drivers and goals are most important to surveyed hematologist-oncologists when selecting a first-line therapy for intensive-induction-eligible AML?
- How do key currently available regimens, including Vyxeos or Rydapt in combination with intensive chemotherapy, perform in terms of key attributes?
- What are the greatest unmet needs and most attractive opportunities in the first-line treatment of intensive-induction-eligible AML?
- What tradeoffs are surveyed hematologist-oncologists willing to make for new and emerging therapies to treat this subpopulation of AML?
PRODUCT DESCRIPTION
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP Simulator.
Markets covered: United States, France, Germany, United Kingdom
Primary research: Survey of 62 U.S. and 31 European hematologist-oncologists fielded in December 2022.
Key companies: Pfizer, Novartis, Jazz Pharmaceuticals
Key drugs: Mylotarg, Rydapt, Vyxeos, cytarabine, daunorubicin, fludarabine, G-CSF, and idarubicin
Table of contents
- Acute Myeloid Leukemia - Unmet Need - Unmet Need - First-Line Intensive-Induction-Eligible Acute Myeloid Leukemia (US/EU)
- Unmet need - first-line intensive-induction-eligible AML - TPP simulator - March 2023
- Executive summary
- Introduction
- Treatment drivers and goals
- Key findings: attribute importance
- Relative importance of efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to surveyed hematologist-oncologists' prescribing decisions in first-line intensive-induction-eligible AML
- Importance of efficacy attributes to prescribing decisions in first-line intensive-induction-eligible AML: United States
- Importance of efficacy attributes to prescribing decisions in first-line intensive-induction-eligible AML: Europe
- Importance of safety and tolerability attributes to prescribing decisions in first-line intensive-induction-eligible AML: United States
- Importance of safety and tolerability attributes to prescribing decisions in first-line intensive-induction-eligible AML: Europe
- Importance of convenience of administration attributes to prescribing decisions in first-line intensive-induction-eligible AML: United States
- Importance of convenience of administration attributes to prescribing decisions in first-line intensive-induction-eligible AML: Europe
- Key findings: stated vs. derived importance
- Stated vs. derived importance of key efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to prescribing decisions in first-line intensive-induction-eligible AML: United States
- Stated vs. derived importance of key efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to prescribing decisions in first-line intensive-induction-eligible AML: Europe
- Product performance against treatment drivers and goals
- Key findings
- Overall performance of key therapies for first-line intensive-induction-eligible AML: United States
- Overall performance of key therapies for first-line intensive-induction-eligible AML: Europe
- Mean overall performance of key therapies for first-line intensive-induction-eligible AML: United States and Europe
- Relative performance of key therapies for first-line intensive-induction-eligible AML across select efficacy attributes: United States
- Relative performance of key therapies for first-line intensive-induction-eligible AML across select efficacy attributes: Europe
- Relative performance of key therapies for first-line intensive-induction-eligible AML across select safety and tolerability attributes: United States
- Relative performance of key therapies for first-line intensive-induction-eligible AML across select safety and tolerability attributes: Europe
- Relative performance of key therapies for first-line intensive-induction-eligible AML across select convenience of administration attributes: United States
- Relative performance of key therapies for first-line intensive-induction-eligible AML across select convenience of administration attributes: Europe
- Assessment of unmet need
- Key findings: unmet need in first-line intensive-induction-eligible AML
- Surveyed hematologist-oncologistsu2019 satisfaction with the performance of key therapies for first-line intensive-induction-eligible AML on efficacy, safety and tolerability, convenience of administration, and nonclinical factors: United States
- Surveyed hematologist-oncologistsu2019 satisfaction with the performance of key therapies for first-line intensive-induction-eligible AML on efficacy, safety and tolerability, convenience of administration, and nonclinical factors: Europe
- Surveyed hematologist-oncologists' ascribed level of unmet need across key efficacy attributes in first-line intensive-induction-eligible AML: United States
- Surveyed hematologist-oncologists' ascribed level of unmet need across key efficacy attributes in first-line intensive-induction-eligible AML: Europe
- Surveyed hematologist-oncologists' ascribed level of unmet need across key safety and tolerability attributes in first-line intensive-induction-eligible AML: United States
- Surveyed hematologist-oncologists' ascribed level of unmet need across key safety and tolerability attributes in first-line intensive-induction-eligible AML: Europe
- Surveyed hematologist-oncologists' ascribed level of unmet need across key convenience of administration attributes in first-line intensive-induction-eligible AML: United States
- Surveyed hematologist-oncologists' ascribed level of unmet need across key convenience of administration attributes in first-line intensive-induction-eligible AML: Europe
- Key findings: unmet need in first-line intensive-induction-eligible AML and related indications
- Surveyed hematologist-oncologists' ascribed level of unmet need in first-line intensive-induction-eligible AML and related indications: United States
- Surveyed hematologist-oncologists' ascribed level of unmet need in first-line intensive-induction-eligible AML and related indications: Europe
- Opportunity analysis
- Target product profiles
- Appendix
Related Market Assessment Reports
Report
Acute Coronary Syndrome – Unmet Need – Unmet Need – Acute Coronary Syndrome: Secondary Prevention, on Top of Statin Treatment (US/EU)
This report covers the 12-month post-hospital management of secondary prevention in ACS patients. Reducing cardiovascular (CV) residual risk and achieving guideline-recommended LDL-C targets…
Report
Multiple Sclerosis – Unmet Need – Unmet Need – Multiple Sclerosis: Nonrelapsing Secondary-Progressive Multiple Sclerosis (US/EU)
No treatments are approved for nonrelapsing secondary-progressive multiple sclerosis (nrSP-MS), an MS disease course in which physical disability accumulates in the absence of superimposed relapses…
Report
Myasthenia Gravis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Myasthenia Gravis (US)
Myasthenia gravis (MG) is a rare neuromuscular disorder caused by specific autoantibodies at the neuromuscular junction; in most patients, these autoantibodies target acetylcholine receptors. MG is…
Report
Osteoarthritic Pain – Current Treatment – Treatment Algorithms: Claims Data Analysis – Osteoarthritic Pain (US)
Osteoarthritic (OA) pain affects more than 30 million people in the United States, and the aging population and rising obesity rates are expected to drive further increases. Current treatments,…
